LUNAC Therapeutics has spun out of the University of Leeds with €3.09M of funding from the university and the VC firm Epidarex Capital for the development of anticoagulants with a lower risk for bleeding than those currently available.
The new anticoagulants will target activated factor XII, a protein which company founders Helen Philippou and Richard Foster have spent a decade researching at the University of Leeds with the support of the Wellcome Trust, British Heart Foundation, and the Medical Research Council.